We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Intron-A/Aldara Combination Therapy for Basal Cell Carcinoma (BCC)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00581425
First Posted: December 27, 2007
Last Update Posted: October 12, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Stephen Tucker, The University of Texas Health Science Center, Houston
December 21, 2007
December 27, 2007
October 12, 2017
December 2007
September 2011   (Final data collection date for primary outcome measure)
resolution of basal cell carcinoma [ Time Frame: 2 years ]
Same as current
Complete list of historical versions of study NCT00581425 on ClinicalTrials.gov Archive Site
resolution of basal cell carcinoma at a lower cost and less inflammation. [ Time Frame: 2 years ]
resolution of basal cell carcinoma [ Time Frame: 2 years ]
Not Provided
Not Provided
 
Intron-A/Aldara Combination Therapy for Basal Cell Carcinoma (BCC)
Intron-A/Aldara Combination Therapy for BCC Excluding the Face and Scalp
A trial to see if BCC excluding the scalp and face can be treated successfully with a combination therapy of Intron-A and Aldara.
Not Provided
Interventional
Phase 4
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Basal Cell Carcinoma
Biological: Imiquimod and Interferon alpha
Imiquimod first two weeks and last two weeks. Interferon middle five weeks.
Experimental: Treated
Intervention: Biological: Imiquimod and Interferon alpha
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
49
September 2011
September 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Nodular or superficial basal cell carcinoma on the skin excluding scalp or face

Exclusion Criteria:

  • Pregnancy
Sexes Eligible for Study: All
Child, Adult, Senior
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00581425
HSC-MS-06-0478
OSP-24412
Yes
Not Provided
Not Provided
Stephen Tucker, The University of Texas Health Science Center, Houston
The University of Texas Health Science Center, Houston
Not Provided
Principal Investigator: Stephen B Tucker, M.D. University of Texas Health Science Center of Houston Dermatology Clinic
The University of Texas Health Science Center, Houston
January 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP